Treatment adherence and anxiety levels of bronchiectasis patients in the COVID-19 pandemic

It has been reported that during the coronavirus disease-2019 (COVID-19) pandemic, bronchiectasis patients were adversely affected due to their limited respiratory functions and acute exacerbations which were triggered by viral infections. The increased concern in the population during the pandemic has affected the attitudes of people toward avoiding disease and patients’ treatment compliance. It is unclear whether treatment adherence and anxiety levels of bronchiectasis patients have changed during the pandemic. We aimed to evaluate treatment adherence and anxiety levels in patients with bronchiectasis. A cross-sectional survey was conducted between May and November 2021. A total of 123 patients with bronchiectasis and 110 adults without chronic diseases were included in the control group. Patient demographic information, bronchiectasis follow-up data, and COVID-19 history were recorded. Then, patients filled out “MARS-5 Index” (Medical Adherence Report Scale-5), Beck Anxiety Scale and the Effect of Events Scale (IES-R). Responses of questionnaires were statistically analyzed. Our results showed that the majority of patients with bronchiectasis had high Medical Adherence Report Scale-5 index total scores during the COVID-19 pandemic (86.2%). The total scores on the Beck Anxiety Scale of bronchiectasis patients who did not have COVID-19 were significantly higher than those who had COVID-19 (P = .04). The total scores on the IES-R were found to be significantly higher in the control group (P < .001). No significant difference was found in the total scores on the Beck Anxiety Scale between the patients and the control group. The bronchiectasis patients had high adherence to their current treatment during the COVID-19 period and were less affected by the pandemic and its psychological effects compared to the healthy population. Furthermore, individuals diagnosed with bronchiectasis who were not infected with COVID-19 demonstrated increased levels of anxiety compared to those who were infected with COVID-19 which may be due to their concern about contracting the disease.

[1]  B. Döme,et al.  [The impact of the COVID-19 epidemic on the course of the most common respiratory diseases]. , 2023, Orvosi Hetilap.

[2]  E. Akıncı,et al.  Effect of chronic lung diseases on mortality of prevariant COVID-19 pneumonia patients , 2022, Frontiers in Medicine.

[3]  Christina S. Thornton,et al.  Assessment of factors and interventions towards therapeutic adherence among persons with non-cystic fibrosis bronchiectasis , 2022, ERJ Open Research.

[4]  C. Olveira,et al.  Impact of the SARS-CoV-2 Virus Pandemic on Patients with Bronchiectasis: A Multicenter Study , 2022, Antibiotics.

[5]  E. Barreiro,et al.  Profile of Clinical and Analytical Parameters in Bronchiectasis Patients during the COVID-19 Pandemic: A One-Year Follow-Up Pilot Study , 2022, Journal of clinical medicine.

[6]  G. Raghu,et al.  Interstitial lung disease before and after COVID-19: a double threat? , 2021, European Respiratory Journal.

[7]  J. Jose,et al.  Medication Adherence and Patients’ Characteristics in Chronic Diseases: A National Multi-Center Study , 2021, Clinical nursing research.

[8]  I. Pavord,et al.  Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study , 2021, The Lancet Respiratory Medicine.

[9]  A. Shoemark,et al.  The Impact of the COVID-19 Pandemic on Exacerbations and Symptoms in Bronchiectasis: A Prospective Study , 2021, American journal of respiratory and critical care medicine.

[10]  M. Metersky Fewer Bronchiectasis Exacerbations during the “Lockdown” for COVID-19: Can We Convert Knowledge into Action? , 2021, American journal of respiratory and critical care medicine.

[11]  N. Hopkinson,et al.  Respiratory patient experience of measures to reduce risk of COVID-19: findings from a descriptive cross-sectional UK wide survey , 2020, BMJ Open.

[12]  Anika Mitchell,et al.  Addressing mental health in patients and providers during the COVID-19 pandemic☆ , 2020, Seminars in Perinatology.

[13]  Ö. Berk,et al.  THE VALIDITY AND RELIABILITY STUDY OF THE TURKISH ADAPTATION OF MEDICAL ADHERENCE REPORT SCALE , 2019, İstanbul Tıp Fakültesi Dergisi.

[14]  U. Connor,et al.  Variation in medication adherence across patient behavioral segments: a multi-country study in hypertension , 2015, Patient preference and adherence.

[15]  E. Mehuys,et al.  Accuracy of the Medication Adherence Report Scale (MARS-5) as a Quantitative Measure of Adherence to Inhalation Medication in Patients With COPD , 2014, The Annals of pharmacotherapy.

[16]  F. Sjöberg,et al.  Psychometric Properties of the Impact of Event Scale-Revised in Patients One Year After Burn Injury , 2010, Journal of burn care & research : official publication of the American Burn Association.

[17]  A. Beck,et al.  An inventory for measuring clinical anxiety: psychometric properties. , 1988, Journal of consulting and clinical psychology.